201 related articles for article (PubMed ID: 29059171)
1. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Araiza-Olivera D; Feng Y; Semenova G; Prudnikova TY; Rhodes J; Chernoff J
Oncogene; 2018 Feb; 37(7):944-952. PubMed ID: 29059171
[TBL] [Abstract][Full Text] [Related]
2. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
5. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
6. RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
[TBL] [Abstract][Full Text] [Related]
7. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
[TBL] [Abstract][Full Text] [Related]
8. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
9. RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC; Uribe-Alvarez C; Chernoff J
Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
[TBL] [Abstract][Full Text] [Related]
10. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
11. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
[TBL] [Abstract][Full Text] [Related]
12. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Dendritic Actin Network Formation in Extended Lamellipodia Drives Proliferation in Growth-Challenged Rac1
Mohan AS; Dean KM; Isogai T; Kasitinon SY; Murali VS; Roudot P; Groisman A; Reed DK; Welf ES; Han SJ; Noh J; Danuser G
Dev Cell; 2019 May; 49(3):444-460.e9. PubMed ID: 31063759
[TBL] [Abstract][Full Text] [Related]
15. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
Riverso M; Montagnani V; Stecca B
Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
[TBL] [Abstract][Full Text] [Related]
16. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal regulation of Rac1 and PAK-1 by HIF-1alpha: a positive-feedback loop promoting pulmonary vascular remodeling.
Diebold I; Petry A; Djordjevic T; Belaiba RS; Fineman J; Black S; Schreiber C; Fratz S; Hess J; Kietzmann T; Görlach A
Antioxid Redox Signal; 2010 Aug; 13(4):399-412. PubMed ID: 20001745
[TBL] [Abstract][Full Text] [Related]
18. TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.
Pang Y; Zhao Y; Wang Y; Wang X; Wang R; Liu N; Li P; Ji M; Ye J; Sun T; Li J; Ma D; Lu F; Ji C
J Exp Clin Cancer Res; 2020 Aug; 39(1):158. PubMed ID: 32795319
[TBL] [Abstract][Full Text] [Related]
19. Constitutive RAC activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression.
Dalton LE; Kamarashev J; Barinaga-Rementeria Ramirez I; White G; Malliri A; Hurlstone A
J Invest Dermatol; 2013 Jun; 133(6):1572-81. PubMed ID: 23337888
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of small molecule Rac1 inhibitors.
Arnst JL; Hein AL; Taylor MA; Palermo NY; Contreras JI; Sonawane YA; Wahl AO; Ouellette MM; Natarajan A; Yan Y
Oncotarget; 2017 May; 8(21):34586-34600. PubMed ID: 28410221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
